Cover Image
市場調查報告書

紡錘體驅動蛋白 (KSP或Eg5):開發中產品分析

Kinesin Spindle Protein (KSP or Eg5) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 358695
出版日期 內容資訊 英文 74 Pages
訂單完成後即時交付
價格
Back to Top
紡錘體驅動蛋白 (KSP或Eg5):開發中產品分析 Kinesin Spindle Protein (KSP or Eg5) - Pipeline Review, H1 2016
出版日期: 2016年04月30日 內容資訊: 英文 74 Pages
簡介

本報告提供全球各國治療紡錘體驅動蛋白 (KSP或Eg5) 所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要的疾病及藥物概要,最新的產業趨勢等資訊。

目錄

  • 簡介
    • 分析範圍
  • 紡錘體驅動蛋白 (KSP/Eg5)的概要
  • 治療藥的開發
    • 臨床實驗中的產品:臨床實驗的各階段
    • 臨床實驗中的產品:各治療領域
    • 臨床實驗中的產品:不同症狀
  • 開發中產品的概要
    • 臨床實驗後期階段的產品
    • 臨床實驗初期階段的產品
  • 各企業開發中的產品
  • 各大學/研究機關開發中的產品
  • 治療藥的評估
    • 單劑治療藥/並用治療藥的情況
    • 各作用機制
    • 各投藥途徑
    • 各分子類型
  • 紡錘體驅動蛋白治療藥的開發企業
    • 4SC AG
    • Alnylam Pharmaceuticals, Inc.
    • Array BioPharma Inc.
    • BIND Therapeutics, Inc.
    • Kyowa Hakko Kirin
    • Merck & Co., Inc.
    • Novartis AG
    • OncoTherapy Science, Inc.
  • 藥物簡介
    • 4SC-205
      • 產品概要
      • 作用機制
      • 研究開發 (R&D)的進展
    • ALN-VSP
    • BIND-267
    • BQS-481
    • filanesib
    • LH-025
    • MK-8267
    • OCVC-01
    • OTSGC-A24
    • Small Molecule to Inhibit Kinesin Spindle Protein for Cancer
    • Small Molecules to Inhibit KSP for Oncology
    • Small Molecules to Inhibit Mitotic Kinesin Eg5 for Ovarian Cancer
    • SRI-35566
    • Vaccine to Target KIF20A, URLC10, CDCA1 for Non-Small Cell Lung Cancer
    • Vaccine to Target URLC10, DEPDC1, FOXM1, KIF20A VEGFR1 and VEGFR2 for Malignant Glioma
  • 開發暫停的計劃
  • 開發中止的計劃
  • 值得注意的最新趨勢·新聞稿 (全10件)
  • 附錄

圖表一覽

目錄
Product Code: GMDHC0014TDB

Summary

Global Markets Direct's, 'Kinesin Spindle Protein (KSP or Eg5) - Pipeline Review, H1 2016', provides in depth analysis on Kinesin Spindle Protein (KSP or Eg5) targeted pipeline therapeutics.

The report provides comprehensive information on the Kinesin Spindle Protein (KSP or Eg5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Kinesin Spindle Protein (KSP or Eg5) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Kinesin Spindle Protein (KSP or Eg5)
  • The report reviews Kinesin Spindle Protein (KSP or Eg5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Kinesin Spindle Protein (KSP or Eg5) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Kinesin Spindle Protein (KSP or Eg5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Kinesin Spindle Protein (KSP or Eg5) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Kinesin Spindle Protein (KSP or Eg5)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Kinesin Spindle Protein (KSP or Eg5) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Kinesin Spindle Protein (KSP or Eg5) Overview
  • Therapeutics Development
    • Kinesin Spindle Protein (KSP or Eg5) - Products under Development by Stage of Development
    • Kinesin Spindle Protein (KSP or Eg5) - Products under Development by Therapy Area
    • Kinesin Spindle Protein (KSP or Eg5) - Products under Development by Indication
  • Kinesin Spindle Protein (KSP or Eg5) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Kinesin Spindle Protein (KSP or Eg5) - Products under Development by Companies
  • Kinesin Spindle Protein (KSP or Eg5) - Products under Development by Universities/Institutes
  • Kinesin Spindle Protein (KSP or Eg5) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Kinesin Spindle Protein (KSP or Eg5) - Companies Involved in Therapeutics Development
    • 4SC AG
    • Alnylam Pharmaceuticals, Inc.
    • Array BioPharma Inc.
    • BIND Therapeutics, Inc.
    • Kyowa Hakko Kirin Co., Ltd.
    • Merck & Co., Inc.
    • Novartis AG
    • OncoTherapy Science, Inc.
  • Kinesin Spindle Protein (KSP or Eg5) - Drug Profiles
    • 4SC-205 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ALN-VSP - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BIND-267 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BQS-481 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filanesib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LH-025 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MK-8267 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OCVC-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OTSGC-A24 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Kinesin Spindle Protein for Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit KSP for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Mitotic Kinesin Eg5 for Ovarian Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRI-35566 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target KIF20A, URLC10, CDCA1 for Non-Small Cell Lung Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target URLC10, DEPDC1, FOXM1, KIF20A VEGFR1 and VEGFR2 for Malignant Glioma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Kinesin Spindle Protein (KSP or Eg5) - Dormant Projects
  • Kinesin Spindle Protein (KSP or Eg5) - Discontinued Products
  • Kinesin Spindle Protein (KSP or Eg5) - Featured News & Press Releases
    • Jun 03, 2015: 4SC Presents Final Results From Phase I AEGIS Trial As Well As Rationale For Daily Dosing Scheme Of 4SC-205 Cancer Compound At ASCO
    • Dec 09, 2014: 4SC reports positive topline data from clinical Phase I trial with 4SC-205 in cancer patients using novel continuous dosing scheme
    • Jul 29, 2013: Motor Protein Revs Up Cell Division
    • Jun 17, 2013: Array BioPharma Announces Positive Interim Results From Combination Trial Of ARRY-520 With Kyprolis At 2013 European Hematology Association Congress
    • Jun 06, 2013: Leukemia & Lymphoma Society Honors Ohi's Research
    • Apr 04, 2013: Array BioPharma Presents Results From Two Ongoing ARRY-520 Clinical Trials In Multiple Myeloma At 2013 International Myeloma Workshop
    • Jan 31, 2013: Tekmira Announces Publication Of Data On LNP Technology In Journal Cancer Discovery
    • Jan 30, 2013: Alnylam And Collaborators Publish Results From Phase I Clinical Trial And Extension Study With ALN-VSP For Treatment Of Liver Cancer
    • Dec 11, 2012: Array BioPharma Provides Updates On Clinical Data On ARRY-520 At 2012 American Society Of Hematology Meeting
    • Dec 05, 2012: 4SC Reports Positive Data From Clinical Phase I Trial With 4SC-205 In Cancer Patients And Initiates Study Amendment
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by 4SC AG, H1 2016
  • Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
  • Pipeline by Array BioPharma Inc., H1 2016
  • Pipeline by BIND Therapeutics, Inc., H1 2016
  • Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
  • Pipeline by Merck & Co., Inc., H1 2016
  • Pipeline by Novartis AG, H1 2016
  • Pipeline by OncoTherapy Science, Inc., H1 2016
  • Dormant Projects, H1 2016
  • Dormant Projects (Contd..1), H1 2016
  • Dormant Projects (Contd..2), H1 2016
  • Dormant Projects (Contd..3), H1 2016
  • Discontinued Products, H1 2016
  • Discontinued Products (Contd..1), H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Top 10 Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top